Nephros vs Sonoma Pharmaceuticals
Nephros and Sonoma Pharmaceuticals are similar in size: $18.8m and $19.5m of revenue in their latest fiscal years. Sonoma Pharmaceuticals grew faster (36.7% against 32.7%). Nephros kept more of each dollar of sales as profit: a net margin of 6.4% against -16.3%.
| Latest fiscal year | NephrosNEPH, 2025 | Sonoma PharmaceuticalsSNOA, 2026 |
|---|---|---|
| Revenue | $18.8m | $19.5m |
| Revenue growth | 32.7% | 36.7% |
| Net income | $1.2m | −$3.2m |
| Operating margin | 6.1% | — |
| Net margin | 6.4% | -16.3% |
| Return on equity | 12.7% | -84.6% |
| Free cash flow | $1.6m | −$4.1m |
| Cash | $5.4m | $2.4m |
| Total debt | $0 | $222,000 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 9 |
| Market value | $35.1m | $5.5m |
| Price vs our value range | — | — |
| Moat score | 31 (Weak) | 26 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |